Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron plus ribavirin regimen comparison in untreated chronic hepatitis C genotype 2 or 3
2004-000820-34Phase 3Completed
- Sponsor
- Integrated Therapeutics Group
- Start
- Jun 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C virus infection (3 arms), sponsored by Integrated Therapeutics Group. Primary endpoint: Sustained HCV virological response. Started Jun 2006; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2004-000820-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000820-34.